Health DiagnosticsHematologyGeneticsBiomedical EngineeringOncologyBiotechnologyManufacturing
Description
Bio-Techne Corporation and its subsidiaries (Bio-Techne) develop, manufacture, and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide.
With the company’s broad product portfolio and…
Analysis
Quality compounder
Bio-Techne Corporation earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.
On valuation, the picture is expensive. The owner-earnings multiple stands at 60.0×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 21% a year, against analyst forecasts of 7%. The market is pricing in far more than analysts expect: heroic expectations.
Growth is tepid; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 202397
98
2023202420252026
All-time high
100
May 2025
All-time low
67
Feb 2024
Average rank
88
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
48
19
15
27
Price/Earnings
17
32
27
20
Price/Book
42
34
27
20
Dividend Yield
97
92
98
96
Value (overall)
89
68
53
35
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.